miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2)

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 2127-2134

  Sun, Xiao hui ^a   Geng, Xiao lin ^a   Zhang, Jun ^a   Zhang, Chao ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

FGF2; Invasion; Migration; miR 646; Osteosarcoma; Proliferation

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MICRORNA;

BONE TUMOR; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA;

EID: 84930919029     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2822-z     Document Type: Article

References (26)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma[M]//pediatric and adolescent osteosarcoma. US: Springer; 2010. p. 3–13.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.
3. Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19(6):1123–30.
4. Yates LA, Norbury CJ, Gilbert RJC. The long and short of microRNA. Cell. 2013;153(3):516–9.
5. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848–56.
6. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.
7. Chow TF, Mankaruos M, Scorilas A, et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol. 2010;183(2):743–51.
8. Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer[M]//microRNA cancer regulation. Netherlands: Springer; 2013. p. 1–20.
9. Zhou Y, Huang Z, Wu S, et al. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res: CR. 2014;33(1):12.
10. Huang J, Gao K, Lin J, et al. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumor Biol. 2014;35(2):1095–100.
11. Zhao G, Cai C, Yang T, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906.
12. Finnerty JR, Wang WX, Hébert SS, et al. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402(3):491–509.
13. Wang WT, Zhao YN, Yan JX, et al. Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery. J Hematol Oncol. 2014;7(1):6.
14. Li W, Liu M, Feng Y, et al. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer, 2014.
15. Zhang H, Zhang Y, Duan HO, et al. TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer. 2008;123(4):810–6.
16. Paterson EL, Kazenwadel J, Bert AG, et al. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15(2):180–IN22.
17. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163.
18. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.
19. Cronauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol. 2003;43(3):309–19.
20. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.
21. Kuhn H, Köpff C, Konrad J, et al. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer. 2004;44(2):167–74.
22. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999;5(5):1063–71.
23. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003;63(18):5754–60.
24. Li D, Wei X, Xie K, et al. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer, 2014.
25. Zhou B, Ma R, Si W, et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett. 2013;333(2):159–69.
26. Ren T, Qing Y, Dai N, et al. Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 2014;105(2):186–94.